SCHEMBL5145231

SCHEMBL5145231

CC(=O)c1ccccc1OCCCCCCCC(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
ALDH1A1 P00352 4/20 0.64
KDM4E B2RXH2 2/20 0.64
MAPT P10636 6/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
HTT P42858 1/20 0.60
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HIF1A Q16665 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NR1I2 O75469 1/20 0.54
CHRM2 P08172 1/20 0.54
CYP3A4 P08684 1/20 0.54
ADRA2A P08913 1/20 0.54
OPRK1 P41145 1/20 0.54
HTR2B P41595 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CNR2 P34972 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4266953 1.00 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2562760 0.94 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13527398 0.89 LMNA (0.69) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2555648 0.89 LMNA (0.70) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL2517739 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL19717846 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5512491 0.87 ALDH1A1 (0.65) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5514981 0.85 ALDH1A1 (0.67) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL13545502 0.85 ALDH1A1 (0.61) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL10102738 0.85 LMNA (0.68) LMNASMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48164-E1 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES INC. (US) 2020-08-18 US disclosed
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 EP disclosed
EP-1478233-B1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECH INC (US) 2016-11-09 EP disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2015-07-23 US disclosed
US-8895777-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES INC (US) 2014-11-25 US disclosed
US-8785381-B2 Oral GLP-1 formulations EMISPHERE TECHNOLOGIES, INC. (US) 2014-07-22 US disclosed
US-8785381-B2 Oral GLP-1 formulations EMISPHERE TECHNOLOGIES, INC. (US) 2014-07-22 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
US-8492330-B2 Formulation comprising GLP-1 EMISPHERE TECHNOLOGIES, INC. (US) 2013-07-23 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 US disclosed
EP-1972349-A1 GLP-1 fusion peptides conjugated to polymer(s), their production and use Biocompatibles UK Limited (GB) 2008-09-24 EP disclosed
US-7309698-B2 Compositions for delivering bisphosphonates EMISPHERE TECHNOLOGIES, INC. (US) 2007-12-18 US disclosed
US-7309698-B2 Compositions for delivering bisphosphonates EMISPHERE TECHNOLOGIES, INC. (US) 2007-12-18 US disclosed
US-7309698-B2 Compositions for delivering bisphosphonates EMISPHERE TECHNOLOGIES, INC. (US) 2007-12-18 US disclosed
EP-1372667-A4 COMPOSITIONS FOR DELIVERING BISPHOSPHONATES EMISPHERE TECH INC (US) 2007-03-14 EP disclosed
US-20040147484-A1 Compositions for delivering bisphosphonates NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2004-07-29 US disclosed
EP-1372667-A2 COMPOSITIONS FOR DELIVERING BISPHOSPHONATES Emisphere Technologies, Inc. (US) 2004-01-02 EP disclosed
WO-2002070438-A2 COMPOSITIONS FOR DELIVERING BISPHOSPHONATES EMISPHERE TECHNOLOGIES, INC. (US) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202296-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 LMNA 4030/4885SMN1; SMN2 3138/4885ALDH1A1 3386/4885
US-20040147484-A1 Compositions for delivering bisphosphonates PHOSPHO1, PTH1R, SOST LMNA 1056/4885SMN1; SMN2 207/4885ALDH1A1 4697/4885
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 LMNA 4030/4885SMN1; SMN2 3138/4885ALDH1A1 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.